Accelerating Innovation at Leica Biosystems

Putting It All Together: Anticipated Long-Term Performance CORE REVENUE GROWTH ACCELERATION 100bps+ MSD+ 5-6% PRE-2019 FUTURE CORE REVENUE GROWTH MSD+ MARGIN EXPANSION STRONG FREE CASH FLOW >100% FCF/NI 50-75BPS OMX ACQUISITIONS FCF+ M&A SPEND TOP QUARTILE EPS GROWTH & COMPOUNDING RETURNS DD+ EPS GROWTH Expect core growth & earnings profile to re-rate higher DANAHER

View entire presentation